Article
Phenotypic manifestations of mutations in genes encoding subunits of cardiac potassium channels.
Division of Arrhythmia and Electrophysiology, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565 Japan.
Circulation Research (impact factor:
9.49).
06/2011;
109(1):97-109.
DOI:10.1161/CIRCRESAHA.110.224600
pp.97-109
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Clinical use of antidepressant therapy and associated cardiovascular risk.
[show abstract] [hide abstract]
ABSTRACT: A number of different psychotropic agents have been associated with an increased risk of cardiovascular disease, and these relationships have been difficult to interpret due to the presence of confounding factors. Recently, there has been renewed interest in the potential for certain antidepressants to cause QT prolongation, which is a predisposing factor for arrhythmia. However, the optimum means of determining QT remains contentious due to discrepancies between methods that may be readily applied in a clinical setting versus more detailed techniques during regulatory assessment. A number of different pharmacological mechanisms might explain the occurrence of adverse cardiac effects, and these differ according to the type of antidepressant agent. Emerging data indicate that citalopram exhibits a dose-effect relationship for QT prolongation. Whereas cardiotoxicity is readily apparent in the context of intentional antidepressant overdose, the occurrence of cardiac effects as a result of therapeutic administration is less certain. Pre-existing cardiac disease and other factors that independently predispose to arrhythmia are important considerations. Therefore, clinical judgment is needed to evaluate the overall risk or benefit of a particular antidepressant in any patient. Close monitoring should be considered for those at greatest risk of QT prolongation and arrhythmia.Drug, Healthcare and Patient Safety 01/2012; 4:93-101.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
cardiac arrhythmia syndromes
cause different types
clinical phenotype
congenital long-QT syndrome
diverse mechanisms
familial atrial fibrillation
gene-specific risk stratification
gene-specific therapy
Genotype-phenotype correlations
include congenital long-QT syndrome
inherited arrhythmia syndromes
molecular structure
potassium channel gene
potassium channel gene mutations
potassium channel gene-related diseases
potassium channel genes
potassium channels
rectifier potassium channels
review article
type 2 congenital long-QT syndrome